CYP3A4/5 and PGP activity in renal transplantation. A study assessing in vivo hepatic and intestinal CYP3A4/5 and PGP activity in kidney transplant recipients and its relationship with genetic and non-genetic variables and the pharmacokinetics and metabolism of Tacrolimus.
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2011
At a glance
- Drugs Fexofenadine (Primary) ; Midazolam (Primary)
- Indications Renal transplant rejection
- Focus Pharmacogenomic; Therapeutic Use
- 09 Aug 2011 New trial record